186 related articles for article (PubMed ID: 38300959)
1. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
[TBL] [Abstract][Full Text] [Related]
2. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
[TBL] [Abstract][Full Text] [Related]
3. Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
Morante Z; Ferreyra Y; Pinto JA; Valdivieso N; Castañeda C; Vidaurre T; Valencia G; Rioja P; Fuentes H; Cotrina JM; Neciosup S; Gomez HL
Front Oncol; 2023; 13():1193927. PubMed ID: 38023174
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience.
De-la-Cruz-Ku G; Luyo M; Morante Z; Enriquez D; Möller MG; Chambergo-Michilot D; Flores L; Luque R; Saavedra A; Eyzaguirre-Sandoval ME; Luján-Peche MG; Noel N; Calderon H; Razuri C; Fuentes HA; Cotrina JM; Neciosup SP; Araujo J; Lema A; Pinto J; Gomez HL; Valcarcel B
PLoS One; 2020; 15(8):e0237811. PubMed ID: 32833983
[TBL] [Abstract][Full Text] [Related]
5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and prognostic evaluation of bone metastasis in triple-negative breast cancer.
Luo A; Wu F; Han R; Huang S; Zhang Y; Jing X; Zhao X
J Cancer Res Ther; 2017; 13(5):778-784. PubMed ID: 29237903
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
9. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
10. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for distant metastasis of patients with primary triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113872
[No Abstract] [Full Text] [Related]
12. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
13. Does addition of postmastectomy radiotherapy improve outcome of patients with pT1-2, N0 triple negative breast cancer as compared to breast conservation therapy?
Raghavan RK; Ibrahim S; Jagathnath Krishna KM; Mathew BS
J Cancer Res Ther; 2019; 15(5):1031-1034. PubMed ID: 31603106
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI
Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651
[TBL] [Abstract][Full Text] [Related]
16. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
17. [Effects of Modified Ruji Recipe in Preventing Relapse and Metastasis of Breast Cancer Patients with Negative Hormone Receptor].
Tian HQ; Wang YJ; Wang B; Pang DM; Jin J; Liang GW; Huang XQ; Chen XZ; Yang YL; Ren G
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2017 Feb; 37(2):169-173. PubMed ID: 30650268
[TBL] [Abstract][Full Text] [Related]
18. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment.
Aydiner A; Sen F; Tambas M; Ciftci R; Eralp Y; Saip P; Karanlik H; Fayda M; Kucucuk S; Onder S; Yavuz E; Muslumanoglu M; Igci A
Medicine (Baltimore); 2015 Dec; 94(52):e2341. PubMed ID: 26717372
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
Reddy SM; Barcenas CH; Sinha AK; Hsu L; Moulder SL; Tripathy D; Hortobagyi GN; Valero V
Br J Cancer; 2018 Jan; 118(1):17-23. PubMed ID: 29235566
[TBL] [Abstract][Full Text] [Related]
20. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
